Based on this mechanism, inhibiting Spop was found to result in an abundance of Pd-L1, and in combination with anti-Pd-1 immunotherapy was found to improve tumor regression and overall survival rates in murine models (Zhang et al., 2018). This evidence concerns the gene PDCD1 and neoplasm.